Tributes after Estee Lauder heir who took the cosmetics business global dies aged 92
Mr Lauder, the oldest son of Estee and Joseph H Lauder, who founded the company in 1946, formally joined the New York business in 1958.
Over more than six decades, he played a key role in transforming the business from a handful of products sold under a single brand in US stores to a multi-brand global giant.
He had held the title of chairman emeritus at the time of his death.
Estee Lauder's products are sold in roughly 150 countries and territories under brand names including Clinique and Aveda, according to the company's latest annual report.
The company generated sales of nearly $16bn (€13.8bn) in the fiscal year ended June 30, 2024, the filing said.
Estee Lauder went public in 1995, but members of the Lauder family still have about 84pc of the voting power of common stock, according to the latest annual filing.
Mr Lauder served as president of The Estée Lauder Companies from 1972 to 1995 and as CEO from 1982 to 1999.
He was named chairman in 1995 and served in that role until June 2009.
Under his stewardship, Lauder created the company's first research and development laboratory, brought in professional management at every level, and was the impetus behind the international expansion, helping to spearhead the company's sales and profits exponentially, according to the company.
Mr Lauder led the launch of many brands including Aramis, Clinique and Lab Series, among others.
Until his death, he remained deeply involved in the company's acquisition strategy, including the acquisitions of such brands as Aveda, Bobbi Brown, Jo Malone London and MAC, the company said.
'Throughout his life, my father worked tirelessly to build and transform the beauty industry, pioneering many of the innovations, trends, and best practices that are foundational to the industry today,' said William P Lauder, son and chair of the board at The Estée Lauder Companies, in a statement.
'He was the most charitable man I have ever known, believing that art and education belonged to everyone, and championing the fight against diseases such as Alzheimer's and breast cancer,' he added.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Independent
17-06-2025
- Irish Independent
Tributes after Estee Lauder heir who took the cosmetics business global dies aged 92
Estee Lauder Companies announced the news and said he died surrounded by family. Mr Lauder, the oldest son of Estee and Joseph H Lauder, who founded the company in 1946, formally joined the New York business in 1958. Over more than six decades, he played a key role in transforming the business from a handful of products sold under a single brand in US stores to a multi-brand global giant. He had held the title of chairman emeritus at the time of his death. Estee Lauder's products are sold in roughly 150 countries and territories under brand names including Clinique and Aveda, according to the company's latest annual report. The company generated sales of nearly $16bn (€13.8bn) in the fiscal year ended June 30, 2024, the filing said. Estee Lauder went public in 1995, but members of the Lauder family still have about 84pc of the voting power of common stock, according to the latest annual filing. Mr Lauder served as president of The Estée Lauder Companies from 1972 to 1995 and as CEO from 1982 to 1999. He was named chairman in 1995 and served in that role until June 2009. Under his stewardship, Lauder created the company's first research and development laboratory, brought in professional management at every level, and was the impetus behind the international expansion, helping to spearhead the company's sales and profits exponentially, according to the company. Mr Lauder led the launch of many brands including Aramis, Clinique and Lab Series, among others. Until his death, he remained deeply involved in the company's acquisition strategy, including the acquisitions of such brands as Aveda, Bobbi Brown, Jo Malone London and MAC, the company said. 'Throughout his life, my father worked tirelessly to build and transform the beauty industry, pioneering many of the innovations, trends, and best practices that are foundational to the industry today,' said William P Lauder, son and chair of the board at The Estée Lauder Companies, in a statement. 'He was the most charitable man I have ever known, believing that art and education belonged to everyone, and championing the fight against diseases such as Alzheimer's and breast cancer,' he added.
The Irish Sun
11-06-2025
- The Irish Sun
Beauty fans race to Primark as they drop £4 dupe of popular £26 dry shampoo – and it's completely aerosol free
PRIMARK is known for its epic beauty dupes. And it seems the store has done it again with a new arrival - a completely aerosol free dry shampoo. Advertisement 4 Primark are sure to find success with this dry shampoo - a £4 dupe of an Aveda one, that costs £26 Credit: TikTok/@ 4 It's perfect for the summer as it absorbs sweat Credit: TikTok/@ 4 The Aveda one is hugely popular, with thousands of positive reviews Credit: Aveda A look at the new product was shared on the Inverness Beauty TikTok page, which posts the latest drops in the Primark beauty and hair departments. In the video, they showed the dry shampoo, which contains hyaluronic acid and "absorbs oils, sweat and volumises hair". It also costs £4 for 54g, compared to £26 for 56g of Aveda's much-loved Shampowder dry shampoo. "I hope it's like the Aveda one!!!" one person wrote in the comments section Advertisement Read more Primark stories "Oooo a trip to Primark for me!" another added. "If you see this, I need to try it!" a third insisted, tagging a friend. Aveda's Shampowder shampoo has long been a favourite among beauty fans - particularly for the fact that it doesn't leave a white residue like its aerosol equivalents. "Perfect for absorbing excess oil, impurities and sweat with powerful plant powders, this dry shampoo powder instantly adds volume and texture to refresh style," Aveda say of the product on their website. Advertisement Most read in Fabulous And the reviews for the pricey product are overwhelmingly positive, with one person writing: "I have been using this product for a few weeks now, I wanted to test it on days where I really needed to rescue my hair! "I have dark brown hair and was worried at first that it comes out a white powder, but very pleased when I found it disappeared when it absorbed the oils. Primark adds brand new Sol De Janeiro dupes to its beauty aisles and they're perfect for keeping you smelling sweet on holiday too "I like that it isn't a spray but found the bottle a bit fiddly, took a little time to get used to." "Love this new dry shampoo format," another added. Advertisement "It gives you good control over how much product to use vs an aggressive aerosol. "Please bring out a dark haired version!" "This is my new go-to dry shampoo!" a third commented. "I love the signature Aveda smell of the formula; it's gentle and pleasant. Advertisement Top Primark summer buys IF you're looking for more Primark summer buys, then you've come to the right place. Shoppers have recently been raving about the Others were desperate to nab the If animal print is your thing, you'll want to check out the The If you're on a budget, these There's And if you plan on heading to the beach, you won't want to miss these "The bottle and application method is so easy to use, it evenly distributes the product and works so well to absorb the excess oil and gives me volume to extend my wash day out by a day." Aveda isn't the only company to release an aerosol-free dry shampoo, however. Stacey Solomon's Rehab brand also has a powder-based formula, but it's still pricey at £24. Despite that, reviewers rave about the Essential Dry Shampoo, with some going as far to call it "one of the best dry shampoos" they've ever used. Advertisement 4 Stacey Solomon's Rehab brand also has an aerosol free dry shampoo that some people call "one of the best" they've ever used Credit: rehab
RTÉ News
03-06-2025
- RTÉ News
'Hope on horizon' as new drugs tested for Alzheimer's treatment
Dementia experts have said that "hope is on the horizon" after a new review shows a rise in the number of potential drugs that could treat or prevent Alzheimer's disease. Some 138 new treatments are being assessed for the treatment and prevention of Alzheimer's. A third of drugs currently being trialled are "repurposed" medications that are already being used to tackle other diseases, including diabetes, multiple sclerosis and cholesterol, according to the new review. One such trial is assessing whether semaglutide, the main ingredient for the weight loss and diabetes drug Ozempic and weight loss drug Wegovy, can slow the progression of dementia. And four late-stage trials are looking at preventing disease. Experts said that drugs targeting amyloid protein build up in the brain, such as lecanemab and donanemab, are "only one part of the overall strategy" as they expressed excitement over the variety of new drugs, which are being tested among patients. The new review of Alzheimer's disease in clinical trials in 2025 found 182 clinical trials assessing the impact of 138 drugs. The number of trials represents an 11% increase on the previous year, according to the review, which was led by an expert from the University of Nevada in the US and has been published in the journal Alzheimer's and Dementia: Translational Research and Clinical Interventions. Commenting on the paper, Dr Sheona Scales, director of research at Alzheimer's Research UK, said: "This year has really given us real cause for optimism." She said that as well as more drugs coming through the pipeline, the treatment targets are "more diverse" and "looking at all stages of the disease". She added: "What this paper is showing us is that the pipeline of drug development is growing, it's diversifying and accelerating." "This latest report shows us that there is hope on the horizon for people with Alzheimer's, building on lecanemab and donanemab." Dr Emma Mead, chief scientific officer of the Oxford Drug Discovery Institute, added: "Today we are at a tipping point in dementia research as we understand more and more about the diseases that drive dementia. "This gives us opportunities to slow and ultimately stop this devastating condition and today's announcement demonstrates that researchers are able to translate these understandings towards potential new treatments." James Rowe, professor of cognitive neurology at the University of Cambridge and consultant neurologist, said: "What strikes me is not just the number of new drugs, which is increasing year on year, but their range of targets (and) the range in which they work, giving us multiple shots on goal." On the drugs which are being investigated for the prevention of disease, Prof Rowe said: "One of the most exciting things of this report is the number of large-scale late-stage trials on prevention. "And the aspiration to prevent, not just treat, is starting to be seen in the figures we see in these charts today." He added: "One way this can work is you take a treatment that you show to be working in people with symptoms with the illness, and then you simply bring it forward by some years. "The ones that are in trial at the moment are really... bringing forward an effective treatment to earlier stage." For instance, people with a genetic risk of Alzheimer's could receive some drugs earlier to see if they protect against the disease. On the repurposing of current drugs, Dr Mead said that it can usually take ten to 15 years for new drugs to be tested and approved for use. "Being able to repurpose drugs licensed for other health conditions could help to accelerate progress and help to open up other avenues to prevent or treat dementia causing diseases," she said. "A really promising example of this is the drug semaglutide, which is currently being trialled in people with mild cognitive impairment." Meanwhile, academics said lecanemab and donanemab, which can be used for treating mild cognitive impairment in Alzheimer's patients, are an "important first step" in the battle against the disease. The treatments were initially approved for UK use by regulators but then deemed not cost-effective for NHS use. The National Institute for Health and Care Excellence (NICE) is taking more evidence on donanemab and lecanemab and is expected to announce its decision in the summer. Dr Scales added: "Lecanemab and donanemab have represented a huge leap forward in our understanding and ability to be able to treat Alzheimer's disease. "What they've done is they've proved that we're able to modify the course of Alzheimer's disease, and what that has done is opened up the door to future treatments that we hope are more effective, easier to deliver and able to deliver for our patients." She said studies are showing "even more complexities" around Alzheimer's and that in the future, people may be treated with a combination of drugs, depending on when they are diagnosed and the type of dementia they have.
